Home » AANEM Director of Wellness Policy Catherine French said.

AANEM Director of Wellness Policy Catherine French said.

The revise concludes that IOM with somatosensory evoked potentials and transcranial electric electric motor evoked potentials is an effective strategy to predict increased risks of serious problems from spinal surgeries plus some upper body surgeries. AANEM Director of Wellness Policy Catherine French said, ‘Evidence-based guidlines help guarantee the best outcomes of medical treatment. The AAN guideline on IOM can not only be of value to your members, but also be good for payers as they review existing reimbursement policies and create such policies for this service in the future.’.. AANEM endorses AAN guideline update on intraoperative monitoring The American Association of Neuromuscular & Electrodiagnostic Medication recently endorsed the American Academy of Neurology guideline update on intraoperative monitoring .Kasner, M.D., Julie A. Johnson, Pharm.D., Jeffrey L. Anderson, M.D., Brian F. Gage, M.D., Yves D. Rosenberg, M.D., Charles S. Eby, M.D., Rosemary A. Madigan, R.N., M.P.H., Robert B. McBane, M.D., Sherif Z. Abdel-Rahman, Ph.D., Scott M. Stevens, M.D., Steven Yale, M.D., Emile R. Mohler, III, M.D., Margaret C. Fang, M.D., Vinay Shah, M.D., Richard B. Horenstein, M.D., Nita A. Limdi, Pharm.D., Ph.D., James A.S. Muldowney, III, M.D., Jaspal Gujral, M.B., B.S., Patrice Delafontaine, M.D., Robert J. Desnick, M.D., Ph.D., Thomas L. Ortel, M.D., Ph.D., Henny H. Billett, M.D., Robert C. Pendleton, M.D., Nancy L. Geller, Ph.D., Jonathan L. Halperin, M.D., Samuel Z. Goldhaber, M.D., Michael D. Caldwell, M.D., Ph.D., Robert M. Califf, M.D., and Jonas H. Ellenberg, Ph.D. For the COAG Investigators: A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing The need for clinical trials before widespread adoption of genotype-guided drug selection and dosing remains widely debated.1-4 Warfarin therapy has served as a model for the potential for pharmacogenetics to improve patient treatment.1 Observational studies have identified two genes, CYP2C9 and VKORC1, that are associated with variation in warfarin maintenance doses.